Publication: Anti-HDV IgM as a marker of disease activity in hepatitis delta
dc.contributor.author | Wranke, Anika | |
dc.contributor.author | Heidrich, Benjamin | |
dc.contributor.author | Ernst, Stefanie | |
dc.contributor.author | Serrano, Beatriz Calle | |
dc.contributor.author | Caruntu, Florin Alexandru | |
dc.contributor.author | Curescu, Manuela Gabriela | |
dc.contributor.author | Yalcin, Kendal | |
dc.contributor.author | Gürel, Selim | |
dc.contributor.author | Zeuzem, Stefan | |
dc.contributor.author | Erhardt, Andreas | |
dc.contributor.author | Lueth, Stefan | |
dc.contributor.author | Papatheodoridis, George V. | |
dc.contributor.author | Bremer, Birgit | |
dc.contributor.author | Stift, Judith | |
dc.contributor.author | Grabowski, Jan | |
dc.contributor.author | Kirschner, Janina | |
dc.contributor.author | Port, Kerstin | |
dc.contributor.author | Cornberg, Markus | |
dc.contributor.author | Falk, Christine S. | |
dc.contributor.author | Dienes, Hans-Peter | |
dc.contributor.author | Hardtke, Svenja | |
dc.contributor.author | Manns, Michael P. | |
dc.contributor.author | Yurdaydin, Cihan | |
dc.contributor.author | Wedemeyer, Heiner | |
dc.contributor.author | HIDIT-2 Study Grp | |
dc.contributor.buuauthor | GÜREL, SELİM | |
dc.contributor.department | Tıp Fakültesi | |
dc.contributor.researcherid | HLH-8209-2023 | |
dc.date.accessioned | 2024-08-15T10:15:33Z | |
dc.date.available | 2024-08-15T10:15:33Z | |
dc.date.issued | 2014-07-29 | |
dc.description.abstract | Background: Hepatitis delta frequently leads to liver cirrhosis and hepatic decompensation. As treatment options are limited, there is a need for biomarkers to determine disease activity and to predict the risk of disease progression. We hypothesized that anti-HDV IgM could represent such a marker.Methods: Samples of 120 HDV-infected patients recruited in an international multicenter treatment trial (HIDIT-2) were studied. Anti-HDV IgM testing was performed using ETI-DELTA-IGMK-2-assay (DiaSorin). In addition, fifty cytokines, chemokines and angiogenetic factors were measured using multiplex technology (Bio-Plex System). A second independent cohort of 78 patients was studied for the development of liver-related clinical endpoints (decompensation, HCC, liver transplantation or death; median follow up of 3.0 years, range 0.6-12).Results: Anti-HDV IgM serum levels were negative in 18 (15%), low (OD<0.5) in 76 (63%), and high in 26 (22%) patients of the HIDIT-2 cohort. Anti-HDV IgM were significantly associated with histological inflammatory (p<0.01) and biochemical disease activity (ALT, AST p<0.01). HDV replication was independent from anti-HDV IgM, however, low HBV-DNA levels were observed in groups with higher anti-HDV IgM levels (p<0.01). While high IP-10 (CXCL10) levels were seen in greater groups of anti-HDV IgM levels, various other antiviral cytokines were negatively associated with anti-HDV IgM. Associations between anti-HDV IgM and ALT, AST, HBV-DNA were confirmed in the independent cohort. Clinical endpoints occurred in 26 anti-HDV IgM positive patients (39%) but in only one anti-HDV IgM negative individual (9%; p = 0.05).Conclusions: Serum anti-HDV IgM is a robust, easy-to-apply and relatively cheap marker to determine disease activity in hepatitis delta which has prognostic implications. High anti-HDV IgM levels may indicate an activated interferon system but exhausted antiviral immunity. | |
dc.description.sponsorship | Federal Ministry of Education & Research (BMBF) | |
dc.description.sponsorship | Hannover Medical School, Germany (IFB-Tx) 01E00802 | |
dc.description.sponsorship | Roche Holding | |
dc.description.sponsorship | Gilead Sciences | |
dc.identifier.doi | 10.1371/journal.pone.0101002 | |
dc.identifier.issn | 1932-6203 | |
dc.identifier.issue | 7 | |
dc.identifier.uri | https://doi.org/10.1371/journal.pone.0101002 | |
dc.identifier.uri | https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0101002 | |
dc.identifier.uri | https://hdl.handle.net/11452/44057 | |
dc.identifier.volume | 9 | |
dc.identifier.wos | 000341307600005 | |
dc.indexed.wos | WOS.SCI | |
dc.language.iso | en | |
dc.publisher | Public Library Science | |
dc.relation.journal | Plos One | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | B-virus | |
dc.subject | Liver-transplantation | |
dc.subject | Interferon | |
dc.subject | Infection | |
dc.subject | Challenges | |
dc.subject | Antibodies | |
dc.subject | Profiles | |
dc.subject | Therapy | |
dc.subject | Cells | |
dc.subject | Science & technology - other topics | |
dc.title | Anti-HDV IgM as a marker of disease activity in hepatitis delta | |
dc.type | Article | |
dspace.entity.type | Publication | |
local.contributor.department | Tıp Fakültesi | |
relation.isAuthorOfPublication | d7a9ea11-69fc-4122-a365-8fb2123512e6 | |
relation.isAuthorOfPublication.latestForDiscovery | d7a9ea11-69fc-4122-a365-8fb2123512e6 |
Files
Original bundle
1 - 1 of 1